COMPANY

ImmunoBlue, LLC

Keywords: oncology other solid tumors

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.11M (STTR Phase II 5R42CA287488-03, continuation, notice Aug 18, 2026). NIH RePORTER 5R42CA287488-03 (Aug 18, 2026)
Evidence (1 event)
- Aug 18, 2026 · NIH RePORTER 5R42CA287488-03
  Organization: IMMUNOBLUE, LLC; City/State: Baltimore, MD; Project number: 5R42CA287488-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1106515; Administering IC: National Cancer Institute; Project title: Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals